ANIX

SEC Filing Summary: CopyTele, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for CopyTele, Inc. (Note: The input metadata referenced "Anixa Biosciences," but the filing text explicitly identifies the registrant as CopyTele, Inc.). The report covers the quarterly period ended April 30, 1999, and the six-month period ended on the same date. The company is classified as a Development Stage Enterprise incorporated in November 1982. Its principal activities involve the development and marketing of the MAGICOM(R) 2000 telecommunications product, the USS-900 digital encryption device, and the e-way peripheral. It also operates a 55% owned joint venture in Shanghai, China (SCE).

Key Financial Metrics

Note: The company reported no sales revenue for the periods presented. Revenue recognition is contingent upon end-user acceptance of products sold to distributors.

Material Changes vs. Prior Period

• Expense Reduction: Selling, general, and administrative expenses (excluding joint venture loss) decreased by approximately $821,000 for the six-month period compared to the prior year. This was driven by reduced engineering supplies, marketing costs, and professional fees.
• Joint Venture Loss: The company's share of the loss from its Shanghai joint venture (SCE) decreased by approximately $94,000 to $113,095 for the six months ended April 30, 1999, compared to $207,381 in the prior year period.
• Interest Income: Interest income declined significantly to $96,775 from $288,767 in the prior year, attributed to lower average funds available for investment and reduced interest rates.
• Cash Position: Cash and cash equivalents decreased by approximately $1.66 million during the six-month period, primarily due to operating cash outflows of $2.64 million.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes current net cash resources (approx. $4.23 million in cash and marketable securities) are sufficient to fund operations into the second quarter of fiscal 2000. However, the company may require additional funding to maintain NASDAQ listing requirements (minimum $4 million net tangible assets) and continue R&D.
• Product Development: The USS-900 encryption device has received UL and FCC approval and is undergoing final testing, with completion expected in June 1999. The e-way peripheral design is complete, with test marketing planned.
• Inventory Risk: Inventory is valued at net realizable value. Management notes there is no assurance that selling prices will not need to be reduced further, which could require additional write-downs.
• Joint Venture Realizability: Approximately $3.6 million is due from the joint venture. Realizability depends on future product sales. If the investment is fully written off, future contributions will be charged directly to operations.
• Year 2000 Issue: The company estimates remediation costs will not exceed $20,000 and does not anticipate a material adverse impact, though a contingency plan is being formulated.

Investor Verification Checklist

• Revenue Recognition: Verify the specific criteria and timeline for recognizing revenue from distributor sales, given the company has recorded $0 sales since inception despite product shipments.
• Inventory Valuation: Assess the risk of inventory write-downs given the limited shipment history and the company's reliance on price reductions to stimulate sales.
• Joint Venture Solvency: Evaluate the financial health of the Shanghai joint venture (SCE) and the likelihood of recovering the $3.6 million receivable.
• Capital Requirements: Confirm the company's ability to raise additional capital to meet NASDAQ net tangible asset requirements and fund the commercialization of the USS-900 and e-way products.
• Executive Compensation: Note that key executives (Chairman, President, and senior personnel) have waived salaries and pension benefits for an undetermined period, which impacts current cash burn but may not be sustainable long-term.